These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 34199565)

  • 1. Comparison of Oncologic Outcomes of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (ddMVAC) with Gemcitabine and Cisplatin (GC) as Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Systematic Review and Meta-Analysis.
    Chung DY; Kang DH; Kim JW; Ha JS; Kim DK; Cho KS
    Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34199565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downstaging of Muscle-Invasive Bladder Cancer Using Neoadjuvant Gemcitabine and Cisplatin or Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin as Single Regimens or as Switch Therapy Modalities.
    Ruplin AT; Spengler AMZ; Montgomery RB; Wright JL
    Clin Genitourin Cancer; 2020 Oct; 18(5):e557-e562. PubMed ID: 32201105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant Cisplatin-based Chemotherapy in Nonmetastatic Muscle-invasive Bladder Cancer: A Systematic Review and Pooled Meta-analysis to Determine the Preferred Regimen.
    Eule CJ; Warren A; Molina Kuna E; Callihan EB; Kim SP; Flaig TW
    Urology; 2024 Jun; 188():118-124. PubMed ID: 38685388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An economic analysis comparing health care resource use and cost of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin versus gemcitabine and cisplatin as neoadjuvant therapy for muscle invasive bladder cancer.
    Montazeri K; Dranitsaris G; Thomas JD; Curran C; Preston MA; Steele GS; Kilbridge KL; Mantia C; Ravi P; McGregor BA; Mossanen M; Sonpavde G
    Urol Oncol; 2021 Dec; 39(12):834.e1-834.e7. PubMed ID: 34162500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downstaging and Survival Outcomes Associated With Neoadjuvant Chemotherapy Regimens Among Patients Treated With Cystectomy for Muscle-Invasive Bladder Cancer.
    Peyton CC; Tang D; Reich RR; Azizi M; Chipollini J; Pow-Sang JM; Manley B; Spiess PE; Poch MA; Sexton WJ; Fishman M; Zhang J; Gilbert SM
    JAMA Oncol; 2018 Nov; 4(11):1535-1542. PubMed ID: 30178038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic review and meta-analysis of neoadjuvant chemotherapy for bladder cancer between ddMVAC and GC regimen.
    Liu T; Jiang G
    Urol Oncol; 2022 May; 40(5):195.e19-195.e25. PubMed ID: 34949512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis.
    Yin M; Joshi M; Meijer RP; Glantz M; Holder S; Harvey HA; Kaag M; Fransen van de Putte EE; Horenblas S; Drabick JJ
    Oncologist; 2016 Jun; 21(6):708-15. PubMed ID: 27053504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695).
    Flaig TW; Tangen CM; Daneshmand S; Alva AS; Lucia MS; McConkey DJ; Theodorescu D; Goldkorn A; Milowsky MI; Bangs R; MacVicar GR; Bastos BR; Fowles JS; Gustafson DL; Plets M; Thompson IM; Lerner SP
    Eur Urol; 2023 Sep; 84(3):341-347. PubMed ID: 37414705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of neoadjuvant chemotherapy with four cycles of dose-dense MVAC followed by radical cystectomy in Korean patients with muscle-invasive or locally advanced urothelial carcinoma of bladder.
    Park K; Lee HJ; Kim TU; Ryu H; Ki YK; Hong YJ; Nam JK
    Asia Pac J Clin Oncol; 2023 Dec; 19(6):739-746. PubMed ID: 37461246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients.
    Hamid ARAH; Ridwan FR; Parikesit D; Widia F; Mochtar CA; Umbas R
    BMC Urol; 2020 Oct; 20(1):158. PubMed ID: 33054762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemcitabine/cisplatin versus methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive bladder cancer: A systematic review and meta-analysis.
    Yu C; Hequn C; Jinbo C; Feng Z; Xiongbing Z; Jian D
    J Cancer Res Ther; 2018; 14(6):1260-1265. PubMed ID: 30488841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of 3 and 4 cycles of neoadjuvant gemcitabine and cisplatin for muscle-invasive bladder cancer: a systematic review and meta-analysis.
    Lu L; Chen C; Cheng H; Ding H; Tian J; Wang H; Wang Z
    BMC Cancer; 2023 Nov; 23(1):1066. PubMed ID: 37932689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic Review and Meta-Analysis of Cisplatin Based Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer.
    Benkhadra R; Nayfeh T; Patibandla SK; Peterson C; Prokop L; Alhalabi O; Murad MH; Mao SS
    Bladder Cancer; 2022; 8(1):5-17. PubMed ID: 38994516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Open-label phase II to evaluate the efficacy of NEoadjuvant dose-dense MVAC In cOmbination with durvalumab and tremelimumab in muscle-invasive urothelial carcinoma: NEMIO.
    Thibault C; Elaidi R; Vano YA; Rouabah M; Braychenko E; Helali I; Audenet F; Oudard S
    Bull Cancer; 2020 Jun; 107(5S):eS8-eS15. PubMed ID: 32620213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695).
    Flaig TW; Tangen CM; Daneshmand S; Alva A; Lerner SP; Lucia MS; McConkey DJ; Theodorescu D; Goldkorn A; Milowsky MI; Bangs R; MacVicar GR; Bastos BR; Fowles JS; Gustafson DL; Plets M; Thompson IM
    Clin Cancer Res; 2021 May; 27(9):2435-2441. PubMed ID: 33568346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Curative Effect and Survival Assessment Comparing Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin and Cisplatin as Neoadjuvant Therapy for Bladder Cancer: A Systematic Review and Meta-Analysis.
    Wu T; Wu Y; Chen S; Wu J; Zhu W; Liu H; Chen M; Xu B
    Front Oncol; 2021; 11():678896. PubMed ID: 34900663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-invasive Bladder Cancer: Results of a Phase 2 Trial.
    Anari F; O'Neill J; Choi W; Chen DYT; Haseebuddin M; Kutikov A; Dulaimi E; Alpaugh RK; Devarajan K; Greenberg RE; Bilusic M; Wong YN; Viterbo R; Hoffman-Censits JH; Lallas CD; Trabulsi EJ; Smaldone M; Geynisman DM; Zibelman M; Lin J; Kelly WK; Uzzo R; McConkey D; Plimack ER
    Eur Urol Oncol; 2018 May; 1(1):54-60. PubMed ID: 30420974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer.
    McConkey DJ; Choi W; Shen Y; Lee IL; Porten S; Matin SF; Kamat AM; Corn P; Millikan RE; Dinney C; Czerniak B; Siefker-Radtke AO
    Eur Urol; 2016 May; 69(5):855-62. PubMed ID: 26343003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209.
    Kitamura H; Tsukamoto T; Shibata T; Masumori N; Fujimoto H; Hirao Y; Fujimoto K; Kitamura Y; Tomita Y; Tobisu K; Niwakawa M; Naito S; Eto M; Kakehi Y;
    Ann Oncol; 2014 Jun; 25(6):1192-8. PubMed ID: 24669010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer.
    Lee FC; Harris W; Cheng HH; Shenoi J; Zhao S; Wang J; Champion T; Izard J; Gore JL; Porter M; Yu EY; Wright JL
    Adv Urol; 2013; 2013():317190. PubMed ID: 24382958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.